deltatrials

Invasive breast carcinoma Trials in Rochester, United States

Conditions / Invasive breast carcinoma / Rochester, United States

Clinical trials for Invasive breast carcinoma investigate a range of treatment strategies and patient populations.

24 total trials for this combination

Showing top 10 of 24 trials

Trials

NCT ID Title Status Phase
NCT03414970 Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer ACTIVE_NOT_RECRUITING PHASE3
NCT01272037 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer ACTIVE_NOT_RECRUITING
NCT01272037 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer ACTIVE_NOT_RECRUITING
NCT04266249 CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy ACTIVE_NOT_RECRUITING PHASE2
NCT02954874 Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT04379570 Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy ACTIVE_NOT_RECRUITING PHASE3
NCT04001829 Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer ACTIVE_NOT_RECRUITING
NCT01272037 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer ACTIVE_NOT_RECRUITING
NCT04457596 T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial ACTIVE_NOT_RECRUITING PHASE3
NCT02445391 Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy ACTIVE_NOT_RECRUITING PHASE3

Related Pages